CLINICAL ROLE -
Pharmacist and provider perspective on BTK inhibitors for Waldenstrom macroglobulinemia.
EP. 1: Waldenstrom Macroglobulinemia Vs Other Lymphomas
The characteristics of Waldenstrom macroglobulinemia that distinguish the disease from other types of lymphomas.
Watch
EP. 2: The Molecular Pathogenesis of Waldenstrom Macroglublinemia
An overview of the types of biomarkers that play a role in the manifestation of Waldenstrom macroglobulinemia.
EP. 3: When to Initiate Therapy for Waldenstrom Macroglublinemia
The criteria used by hematologists and oncologists to guide decisions to initiate therapy for Waldenstrom macroglobulinemia vs monitor patients with active surveillance.
EP. 4: Novel Therapies for Waldenstrom Macroglublinemia
What pharmacists need to know about the adoption of novel targeted therapies for Waldenstrom macroglobulinemia into regular clinical practice.
EP. 5: Approaches to Managing Progressive Waldenstrom Macroglobulinemia
Recommendations for classifying and treating patients with progressive Waldenstrom macroglobulinemia.
EP. 6: Waldenstrom Macroglobulinemia: First-Line Treatment Decisions
The top considerations of hematologists and oncologists when selecting first-line treatment for patients with Waldenstrom macroglobulinemia.
EP. 7: BTK Inhibitor Treatment Selection in Waldenström Macroglobulinemia
An overview of BTK inhibitors available as first-line therapy for Waldenström macroglobulinemia, and variables that impact treatment selection and the switching of agents throughout the course of therapy.
EP. 8: BTK Inhibitor Dose Adjustments in Waldenström Macroglobulinemia
What pharmacists need to know about BTK inhibitor drug activity, dosing, and interactions in Waldenström macroglobulinemia.
EP. 9: Therapies Under Investigation for Waldenström Macroglobulinemia
The exciting therapies in the pipeline that are thought to target novel mechanisms in Waldenström macroglobulinemia.